These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 29244531)

  • 21. Angiotensin II type 1 receptor blockade: a new development in cardiovascular pharmacology.
    Leary AC; MacDonald TM
    Int J Clin Pract; 1998 Oct; 52(7):475-81. PubMed ID: 10622089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects.
    Blumenfeld JD; Sealey JE; Mann SJ; Bragat A; Marion R; Pecker MS; Sotelo J; August P; Pickering TG; Laragh JH
    Am J Hypertens; 1999 May; 12(5):451-9. PubMed ID: 10342782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vasopeptidase inhibition: a new concept in blood pressure management.
    Burnett JC
    J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antihypertensive Effects of Two Novel Angiotensin I-Converting Enzyme (ACE) Inhibitory Peptides from
    Deng Z; Liu Y; Wang J; Wu S; Geng L; Sui Z; Zhang Q
    Mar Drugs; 2018 Aug; 16(9):. PubMed ID: 30150552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renal and cardio-protective effects of direct renin inhibition: a systematic literature review.
    Lambers Heerspink HJ; Perkovic V; de Zeeuw D
    J Hypertens; 2009 Dec; 27(12):2321-31. PubMed ID: 19727007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiotensin II receptor blockade or deletion of vascular endothelial ACE does not prevent vascular dysfunction and remodeling in 20-HETE-dependent hypertension.
    Garcia V; Joseph G; Shkolnik B; Ding Y; Zhang FF; Gotlinger K; Falck JR; Dakarapu R; Capdevila JH; Bernstein KE; Schwartzman ML
    Am J Physiol Regul Integr Comp Physiol; 2015 Jul; 309(1):R71-8. PubMed ID: 25924878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiotensin I-converting enzyme inhibitory activity of gelatin hydrolysates and identification of bioactive peptides.
    Herregods G; Van Camp J; Morel N; Ghesquière B; Gevaert K; Vercruysse L; Dierckx S; Quanten E; Smagghe G
    J Agric Food Chem; 2011 Jan; 59(2):552-8. PubMed ID: 21174470
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Whey peptide Isoleucine-Tryptophan inhibits expression and activity of matrix metalloproteinase-2 in rat aorta.
    Kopaliani I; Martin M; Zatschler B; Müller B; Deussen A
    Peptides; 2016 Aug; 82():52-59. PubMed ID: 27239047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of angiotensin-converting enzyme inhibitors in vascular modulation: beyond the hypertensive effects.
    Katragadda S; Arora RR
    Am J Ther; 2010; 17(1):e11-23. PubMed ID: 20090429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The future of renin inhibition].
    Uresin AY; Baran E
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiotensin converting enzyme (ACE) inhibitory peptides: production and implementation of functional food.
    De Leo F; Panarese S; Gallerani R; Ceci LR
    Curr Pharm Des; 2009; 15(31):3622-43. PubMed ID: 19925416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-hypertensive Peptide Predictor: A Machine Learning-Empowered Web Server for Prediction of Food-Derived Peptides with Potential Angiotensin-Converting Enzyme-I Inhibitory Activity.
    Kalyan G; Junghare V; Khan MF; Pal S; Bhattacharya S; Guha S; Majumder K; Chakrabarty S; Hazra S
    J Agric Food Chem; 2021 Dec; 69(49):14995-15004. PubMed ID: 34855377
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The antihypertensive effect of peptides: a novel alternative to drugs?
    Hong F; Ming L; Yi S; Zhanxia L; Yongquan W; Chi L
    Peptides; 2008 Jun; 29(6):1062-71. PubMed ID: 18384915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of Angiotensin Converting Enzyme, Angiotensin II Receptor Blocking, and Blood Pressure Lowering Bioactivity across Plant Families.
    Patten GS; Abeywardena MY; Bennett LE
    Crit Rev Food Sci Nutr; 2016; 56(2):181-214. PubMed ID: 24915402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
    Athyros VG; Mikhailidis DP; Kakafika AI; Tziomalos K; Karagiannis A
    Expert Opin Pharmacother; 2007 Apr; 8(5):529-35. PubMed ID: 17376010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renin inhibition--benefit beyond hypertension control.
    Kher V
    J Assoc Physicians India; 2009 Jul; 57():518-20, 525. PubMed ID: 20329413
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of inhibitors of the aspartyl protease renin for the treatment of hypertension.
    Scott BB; McGeehan GM; Harrison RK
    Curr Protein Pept Sci; 2006 Jun; 7(3):241-54. PubMed ID: 16787263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders.
    Krum H; Gilbert RE
    J Hypertens; 2007 Jan; 25(1):25-35. PubMed ID: 17143168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.